Subscribe To

Price Alert Latest News Economic Calendar News

KONEF / Wellbeing says its subsidiary KGK Science partners with Nova Mentis for developing psychedelic drug portfolio

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc, formerly known as Ketamine One, announced that its wholly-owned subsidiary, KGK Science Inc, has formed a tactical partnership with Nova Mentis Life Science Corp to help develop Nova's psychedelic drug portfolio in Canada. Nova is a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Read More

Demo Live Account See Partner Details

Content Topics

Infotel

Sa

0oqq

Wellbeing

Subsidiary

Science

Partners

Mentis

Developing

Psychedelic

Portfolio

Stock

KONEF

Posted: Jan 27 2022, 09:04

Author Name: Proactive Investors

KONEF News

By Proactive Investors
June 19, 2023

Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Card

By Proactive Investors
April 18, 2023

Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced pati

By Proactive Investors
March 8, 2023

Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled

By Proactive Investors
February 15, 2023

Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed preclinical safety studies fo

By Proactive Investors
February 14, 2023

Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said its wholly-owned subsidiary KGK Sciences Inc. has received an exemption under Section 56

By Proactive Investors
December 23, 2022

Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome

Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection le

By Proactive Investors
December 8, 2022

Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide canna

By Proactive Investors
December 6, 2022

Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response

Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that a clinical study conducted by wholly-owned subsidiary KGK Science Inc has shown

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.